Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 14/20 | 0.51 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 3/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CDK7 | P50613 | 1/20 | 0.43 |
| ▸ | STAT6 | P42226 | 1/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16570151 | 0.89 | ULK1 (0.47) | ULK1KIF11PTK2PTK2BCDK1 | |
| SCHEMBL16570550 | 0.82 | FGFR4 (0.64) | ULK1KIF11PTK2PTK2BCDK1 | |
| SCHEMBL16570904 | 0.82 | ULK1 (0.46) | ULK1PTK2PTK2BCDK1CCNB1 | |
| SCHEMBL16571159 | 0.81 | PTK2 (0.56) | ULK1PTK2PTK2BCDK1CCNB1 | |
| SCHEMBL16570623 | 0.81 | PTK2 (0.46) | ULK1PTK2PTK2BCDK1CCNB1 | |
| SCHEMBL16570440 | 0.81 | ULK1 (0.48) | ULK1PTK2PTK2BCDK1CCNB1 | |
| SCHEMBL16570339 | 0.80 | PTK2 (0.55) | ULK1KIF11PTK2PTK2BCDK1 | |
| SCHEMBL16570750 | 0.77 | PTK2 (0.66) | ULK1PTK2PTK2BCDK1CDK7 | |
| SCHEMBL16570701 | 0.77 | ULK1 (0.47) | ULK1KIF11PTK2PTK2BCDK1 | |
| SCHEMBL16570753 | 0.76 | PTK2 (0.43) | ULK1PTK2PTK2BSTAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | claimed |
| WO-2015038417-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | claimed |
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | ASANA BIOSCIENCES, LLC (US) | 2016-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160222014-A1 | COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS | SRC, PTK2, FYN | ULK1 769/4885KIF11 3206/4885PTK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.